Yuko Hosoe

Supplementary Figure S3 shows the generation and characterization of CDK12 knockdown cell lines using short hairpin RNA (shRNA) in human uterine serous carcinoma and mouse endometrial carcinoma models, including validation of CDK12 protein reduction and effects on cell proliferation.

Supplementary Figure S5 shows that short-term CDK12/13 inhibition by CTX-439 induces DNA damage and enhances cisplatin sensitivity without affecting short-term cell viability in uterine serous carcinoma cell lines.

Supplementary Figure S6 shows dose–response analyses of CTX-439 and olaparib, alone or in combination at different molar ratios, demonstrating enhanced cytotoxic effects of combination treatment in uterine serous carcinoma cell lines.

Supplementary Figure S4 shows suppression of HR-related gene expression and associated protein changes following CTX-439 treatment in uterine serous carcinoma cell lines, as assessed by RT–qPCR and Western blotting.

Supplementary Figure S1 shows RNA-seq–based analyses of transcriptional changes induced by CTX-439 treatment, including pathway enrichment analyses across multiple USC xenograft models and volcano plots highlighting representative cell cycle–related genes.

Supplementary Figure S2 shows HRD status, CDK12 copy number alterations, and related genomic features in uterine serous carcinoma, including correlations with HRD scores and survival analyses in the TCGA and Kyoto University cohorts.

Supplementary Figure S7 shows longitudinal body weight monitoring in mice bearing ARK2 xenografts treated with vehicle, CTX-439, olaparib, or their combination, demonstrating no significant treatment-related weight loss during the dosing period.

Supplementary Table S2 shows the molecular and genomic characteristics of uterine serous carcinoma PDX models, including HRD scores, TP53 immunohistochemistry status, gene mutations, and ERBB2 copy number alterations.

Supplementary Table S1 shows the primer and probe information used for RT–qPCR analyses and the primary and secondary antibodies used for western blotting in this study.

Supplementary Table S3 shows genes that meet stringent differential expression criteria following CTX-439 treatment, defined by adjusted p value 0.585.